Wissenschaftlerin mit Pipette in einem hellen biomedizinischen Labor

Projekt

Life Saving Technology for Thoracic Trauma Treatment and Post Operative Drainage

Thoracic trauma is the 1st cause of accidental death globally, with a mortality rate of 60% in polytraumatic patients. The time of treatment is crucial. 80% of patients can be potentially saved if they are treated in 1h. However, current solutions to treat it are limited and static for the last 30-50 years. C-LANT is…

Thoracic trauma is the 1st cause of accidental death globally, with a mortality rate of 60% in polytraumatic patients. The time of treatment is crucial. 80% of patients can be potentially saved if they are treated in 1h. However, current solutions to treat it are limited and static for the last 30-50 years. C-LANT is a unique self-fixating, a-traumatic and multifunctional device tackling this unmet need by offering a safe, fast, easy to use, multifunctional and cost-effective tool for treating any type of chest trauma or postoperative drainage following major thoracic and abdominal procedures. It reduces the procedure time by 20x and saves up to €2.6Bn associated with additional tube replacement (EU).

With the EIC support Vigor aims to accelerate the clinical validation and scaling-up of C-LANT, providing a global impact to healthcare systems, clinicians, and patients. C-LANT will be part of the growing Emergency Medical Devices and the Surgical Drains markets (total valued >40B -2030)

Themengebiete

Unternehmen